Population Pharmacokinetics and Pharmacodynamics of Ontamalimab (SHP647), a Fully Human Monoclonal Antibody Against Mucosal Addressin Cell Adhesion Molecule‐1 (MAdCAM‐1), in Patients With Ulcerative Colitis or Crohn's Disease

What Is the Risk of Progressive Multifocal Leukoencephalopathy in Patients With Ulcerative Colitis or Crohn’s Disease Treated With Vedolizumab?

(2018) Timothy Card et al.   INFLAMMATORY BOWEL DISEASES

Targeting endothelial ligands: (ICAM-1/Alicaforsen, MAdCAM-1)

(2018) Walter Reinisch et al.   Journal of Crohns & Colitis

Effect of PF-00547659 on Central Nervous System Immune Surveillance and Circulating β7+ T Cells in Crohn’s Disease: Report of the TOSCA Study

(2017) Geert D’Haens et al.   Journal of Crohns & Colitis

Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial

(2017) Séverine Vermeire et al.   LANCET

Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease

(2015) M. Rosario et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Pharmacokinetics, Pharmacodynamics and Physiologically-Based Pharmacokinetic Modelling of Monoclonal Antibodies

(2013) Miroslav Dostalek et al.   CLINICAL PHARMACOKINETICS

Natalizumab and Progressive Multifocal Leukoencephalopathy

(2010) Clemens Warnke et al.   ARCHIVES OF NEUROLOGY

Progressive Multifocal Leukoencephalopathy in Patients on Immunomodulatory Therapies

(2009) Eugene O. Major   Annual Review of Medicine

Treatment of Active Crohn's Disease With MLN0002, a Humanized Antibody to the α4β7 Integrin

(2008) Brian G. Feagan et al.   Clinical Gastroenterology and Hepatology

Approximations of the target-mediated drug disposition model and identifiability of model parameters

(2008) Leonid Gibiansky et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS